Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 7/20 | 0.57 |
| ▸ | KCNJ5 | P48544 | 7/20 | 0.57 |
| ▸ | KCNJ3 | P48549 | 7/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.51 |
| ▸ | HCK | P08631 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16866561 | 0.89 | KCNJ6 (0.56) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL16859839 | 0.84 | MAPK14 (0.73) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL16866578 | 0.82 | MAPK14 (0.57) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL1012856 | 0.82 | KCNJ6 (0.58) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL16866575 | 0.81 | MAPK14 (0.41) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL18593709 | 0.80 | MAPK14 (0.49) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL16859864 | 0.80 | MAPK14 (0.62) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL16859866 | 0.79 | KCNJ6 (0.69) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL15490413 | 0.78 | KCNJ6 (0.65) | KCNJ6KCNJ5KCNJ3MAPK14MAPK13 | |
| SCHEMBL378957 | 0.78 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219489-A2 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2021-07-15 | — | — | US | disclosed |
| EP-2875014-B1 | ANTI-MUCUS DRUGS AND USES THEREFOR | UNIV WASHINGTON (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9187470-B2 | Anti-mucus drugs and uses therefor | WASHINGTON UNIVERSITY (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187470-B2 | Anti-mucus drugs and uses therefor | WASHINGTON UNIVERSITY (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-02 | — | — | US | disclosed |
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | KCNJ6 3094/4885KCNJ5 3479/4885KCNJ3 2968/4885 |
| US-20150183777-A1 | ANTI-MUCUS DRUGS AND USES THEREFOR | MAPK13, MAPK11, MUC1 | KCNJ6 2735/4885KCNJ5 2821/4885KCNJ3 2794/4885 |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | KCNJ6 3094/4885KCNJ5 3479/4885KCNJ3 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.